Julie Clark, M.D.

Julie Clark, M.D. is Adverum’s acting chief medical officer, responsible for clinical development strategy and execution, including initiation of planned global Phase 3 clinical trials for ADVM-022 in wet AMD and the ongoing INFINITY Phase 2 clinical trial for ADVM-022 in DME. Over the course of her career, she has worked on clinical development programs and commercial launch initiatives for new therapies for ocular diseases, including Eylea® and BEOVU®. Previously, she worked with Novartis over a five-year period in positions of increasing responsibility. As lead medical director – retina, she was responsible for the Phase 3b clinical trial for BEOVU® and served as medical lead for cross-functional team initiatives for product launch. Earlier, she was medical director, U.S. medical affairs for ThromboGenics, where she supported the Jetrea® launch and late-stage clinical studies. Previously, she worked with Regeneron Pharmaceuticals, Inc., where as associate director, medical affairs – ophthalmology she supported the clinical development and commercial launch of Eylea®. Before Regeneron, she worked with ISTA Pharmaceuticals as medical affairs product director and helped align strategy and communications for Xibrom®/Bromday®, Bepreve®, Istalol®, Vitrase®. Dr. Clark earned an M.D. from Wake Forest University School of Medicine and a B.S. in Biology from Wake Forest University. In addition, she holds an M.S. in Biotechnology from the Center for Biotechnology Education and Advanced Biotechnology Studies from Johns Hopkins University.